Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0H1BQ
|
|||
Drug Name |
PMID27539678-Compound-14
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
AJINOMOTO CO., INC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H32N2O2
|
|||
Canonical SMILES |
CC1(CCC(=O)C(=C1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCCC5CO)C
|
|||
InChI |
1S/C28H32N2O2/c1-28(2)11-10-27(32)25(16-28)21-6-3-5-19(13-21)20-8-9-26-22(14-20)15-23(29-26)17-30-12-4-7-24(30)18-31/h3,5-6,8-9,13-16,24,29,31H,4,7,10-12,17-18H2,1-2H3/t24-/m1/s1
|
|||
InChIKey |
PNODTUCQTPQANY-XMMPIXPASA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sphingosine kinase 1 (SPHK1) | Target Info | Inhibitor | [1] |
Target's Patent Info | Sphingosine kinase 1 (SPHK1) | Target's Patent Info | [1] | |
BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
KEGG Pathway | Sphingolipid metabolism | |||
Metabolic pathways | ||||
Calcium signaling pathway | ||||
Sphingolipid signaling pathway | ||||
VEGF signaling pathway | ||||
Fc gamma R-mediated phagocytosis | ||||
Tuberculosis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Panther Pathway | Angiogenesis | |||
VEGF signaling pathway | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
Beta3 integrin cell surface interactions | ||||
S1P1 pathway | ||||
Sphingosine 1-phosphate (S1P) pathway | ||||
PDGFR-beta signaling pathway | ||||
Reactome | Sphingolipid de novo biosynthesis | |||
VEGFR2 mediated cell proliferation | ||||
WikiPathways | Signal Transduction of S1P Receptor | |||
Protein folding | ||||
Sphingolipid Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.